The collagen-tailed form of acetylcholinesterase (A 12 -AChE) appears to be localized at the neuromuscular junction in association with the transmembrane dystroglycan complex through binding of its collagenic tail (ColQ) to the proteoglycan perlecan. The heparan sulfate binding domains (HSBD) of ColQ are thought to be involved in anchoring ColQ to the synaptic basal lamina. The C-terminal domain (CTD) of ColQ is also likely involved, but there has been no direct evidence. Mutations in COLQ cause endplate AChE deficiency in humans. Nine previously reported and three novel mutations are in CTD of ColQ, and most CTD mutations do not abrogate formation of A 12 -AChE in transfected COS cells. Patient endplates, however, are devoid of AChE, suggesting that CTD mutations affect anchoring of ColQ to the synaptic basal lamina. Based on our observations that purified AChE can be transplanted to the heterologous frog neuromuscular junction, we tested insertion competence of nine naturally occurring CTD mutants and two artificial HSBD mutants. Wild-type human A 12 -AChE inserted into the frog neuromuscular junction, whereas six CTD mutants and two HSBD mutants did not. Our studies establish that the CTD mutations indeed compromise anchoring of ColQ and that both HSBD and CTD are essential for anchoring ColQ to the synaptic basal lamina.
Acetylcholinesterase (AChE) 1 terminates cholinergic transmission by hydrolyzing the neurotransmitter acetylcholine. In vertebrates, AChE is encoded by a single gene whose mRNA can be alternatively spliced to yield several forms that differ in their C-terminal domains but share identical catalytic N-terminal domains that compose 95% of their sequence (reviewed in Refs. 1-3). Molecular studies have identified three such variants in mammals, AChE T , AChE H , and AChE R , of about 80 kDa each. In adult mammalian brain and muscle, post-translational processing of AChE T produces secreted monomers, dimers, and tetramers as well as membrane-bound and extracellular matrix-associated oligomers. In skeletal muscle the predominant species of AChE present at the neuromuscular junction (NMJ) is the asymmetric A 12 form (4), consisting of three tetramers of the AChE T variant covalently linked to a triple helical collagen-like tail (ColQ). ColQ is encoded by a separate gene (5, 6) and is essential for the accumulation of AChE at the NMJ (7) .
Several lines of evidence, including in vitro and in culture binding studies, as well as studies using genetically modified mice, indicate that the heparan sulfate proteoglycan perlecan is responsible for localizing AChE on the synaptic basal lamina. Initially, the localization of the collagen-tailed AChE forms was thought to take place via electrostatic interactions with the polyanionic components of the extracellular matrix (8) or heparan sulfate proteoglycans (9, 10 , and for review see Ref. 11 ). Our current model of extracellular matrix specialization at the NMJ suggests that the collagen-tailed AChE form is localized in association with the transmembrane dystroglycan complex via binding of its collagen-like tail to the proteoglycan perlecan. Several studies support this view. First, the heparan sulfate proteoglycan perlecan, a major constituent of skeletal muscle basal lamina, colocalizes with acetylcholine receptors (AChR) both at the NMJ in vivo and in culture (12) (13) (14) . Second, studies utilizing monoclonal antibodies or rhodamine-conjugated fasciculin to visualize AChE together with anti-perlecan monoclonal antibodies show that A 12 -AChE binds to, and colocalizes with, perlecan in vivo and in cultured muscle cells (15) . Third, perlecan binds to dystroglycan (DG) and clusters at the sites of nerve-muscle contact (16, 17) . Asymmetric AChE is thought to be mobilized to the NMJ through interactions with DG and the cytoskeletal linking proteins underlying the postsynaptic membrane. Indeed, when Xenopus muscle cells are innervated after the addition of asymmetric quail A 12 -AChE, and clustering of A 12 -AChE is tracked via fluorescence microscopy, A 12 -AChE, like AChR, is recruited to the NMJ on innervation (15) . Finally, muscle fibers devoid either of DG (18) or of perlecan (19) have no detectable AChE at the NMJ. Together, these results suggest that the initial localization of AChE to the postsynaptic density occurs via a perlecan-and DG-mediated clustering process. Once localized, AChE is thought to form a more permanent, possibly covalent interaction at sites of nerve-muscle contact as evidenced at mammalian NMJs by a "non-extractable AChE pool" (20) . Although questions remain regarding the precise mechanism of AChE localization and attachment at the NMJ, knowledge gleaned from studies in patients with endplate AChE deficiency suggests that the CTD of ColQ is essential in this process (21) (22) (23) .
In endplate AChE deficiency, patient endplates are devoid of asymmetric forms of AChE (24) . The causative molecular defects reside in COLQ (21) (22) (23) 25) and not in ACHE T (26) . Expression studies in COS cells of genetically engineered ColQ mutants along with wild-type AChE T reveal four categories of COLQ mutations (23) as follows: 1) N-terminal mutations that prevent association of AChE T with ColQ; 2) collagen domain truncation mutations that prevent the formation of A 12 ; 3) a CTD missense mutation that prevents triple helical association of ColQ; and 4) CTD mutations that do not abolish A 12 formation but likely affect insertion of ColQ into the synaptic basal lamina. Seven previously reported CTD mutations belong to the fourth category: two nonsense mutations (R315X (22) and Q371X (23)), three missense mutations (D342E, R410Q, and C444Y) (23) , and two splice site mutations (IVS15ϩ1G3 A (23) and IVS16ϩ3A3 G (22)) (Table I) . These mutations produce either reduced amounts (R315X and IVS15ϩ1G3 A) or essentially normal amounts (Q371X, D342E, R410Q, C444Y, and IVS16ϩ3A3 G) of asymmetric AChE in transfected COS cells. Patients carrying D342E (case 2 in Ref. 23 or case 2 in Ref. 24) and carrying both R410Q and C444Y (case 7 in Ref. 23 ), however, express no AChE at intercostal muscle endplates. Y430S also likely belongs to the fourth category, because A 12 form is present in muscle extracts but AChE is barely detectable at the NMJ, but Y430S is not examined by expression studies (21) . These findings imply that CTD mutations affect anchoring of the collagen-tailed AChE to the NMJ, but direct experimental evidence has been lacking.
Based on our observations that purified, collagen-tailed AChE can be transplanted to heterospecific synapses (27) , and to determine the respective roles of the HSBDs and CTD in AChE localization and attachment at the NMJ, we tested the insertion competence of five previously reported (R315X, Q371X, D342E, R410Q, and C444Y) and three novel (S312G, R410P, and E415G) CTD mutants, and two HSBD mutants of human ColQ, at the frog NMJ. All of the CTD mutations have been identified in patients with endplate AChE deficiency. The HSBD mutants were engineered to examine the necessity of the HSBDs of ColQ for insertion. We also studied in vitro binding of the two HSBD mutants to purified perlecan. Our results indicate that the HSBD of ColQ is necessary but not sufficient for attachment of AChE at the NMJ, and the CTD of ColQ is essential for insertion of this molecule into the synaptic basal lamina.
EXPERIMENTAL PROCEDURES
Patients (Pts)-Clinical features and endplate studies in Pts 1 and 2 were reported previously as cases 5 and 3 by Hutchinson et al. (24) . Neither patient expressed AChE at the NMJ. Pt 3 is a 3-year-old girl with moderate myasthenic symptoms including eyelid ptosis, limb/ neck/axial muscle weakness, and fluctuating hyperlordosis. No endplate studies were available from Pt 3.
Mutation Analysis-Genomic DNA and mRNA were isolated from muscle specimens as described (28) . Genomic DNA was isolated from blood from family members with the QIAamp Blood kit (Qiagen). We directly sequenced 17 constitutive and 2 alternatively transcribed COLQ exons and their flanking regions with ABI377 DNA sequencer as described previously (25) .
Construction of Expression Vectors-Human ACHE T and COLQ cDNAs were cloned and introduced into a cytomegalovirus-based mammalian expression vector pTargeT (Promega) (25) . Each CTD mutation, as well as S312G/R410Q double mutations, was introduced into COLQ cDNA using the QuikChange site-directed mutagenesis kit (Stratagene). Fig. 1 shows positions of the CTD mutations introduced into the human COLQ cDNA. We similarly constructed artificial HSBD mutants. pTargeT-ColQ-HSBD-del carries the deletion of RKG at codons 130 -132 in the first HSBD and deletion of KRG at codons 235-237 in the second HSBD. pTargeT-ColQ-HSBD-NQGG harbors 8 missense codons: NQGG substitution for RKGR at codons 130 -133 in the first HSBD and NQGG substitution for KRGK at codons 235-238 in the second HSBD. For each construct, the presence of the desired mutation and absence of unwanted artifacts were confirmed by sequencing the entire insert.
RT-PCR to Test Aberrant Splicing of Exon 16 -To examine if E415G causes aberrant splicing of exon 16, we amplified a cDNA fragment with 5Ј-CAGCTGACCCCTTTCTACCC-3Ј in exon 15 and 5Ј-AGCGGCAGG-GCGTGGAGT-3Ј in exon 17 using mRNA extracted from an endplateenriched muscle biopsy sample of Pt 1 (Table I) . A normally spliced transcript would yield a 286-bp fragment, whereas an exon 16-skipped would give rise to a 183-bp fragment.
To identify the allelic origin of the normally spliced transcript, we next performed allele-specific RT-PCR. The R410Q allele-specific forward primer was 5Ј-CTACTGTGGAGATGGTCAaCA-3Ј, and the E415G allele-specific forward primer was 5Ј-CCGGCATGAGGGTGTc-GG-3Ј. Lowercase letters at position Ϫ3 represent artificial mismatches to enhance discrimination of the two alleles. The reverse primer was 5Ј-AGCGGCAGGGCGTGGAGT-3Ј in exon 17. The PCR protocol comprised 35 cycles of reactions at the annealing temperature of 60°C. The R410Q-and E415G-specific primers would yield 149-and 131-bp fragments, respectively. We tested these allele-specific primers using genomic DNA of Pt 1 and the family members.
Construction of COLQ Minigenes for Pre-mRNA Splicing Analysis-A 5-kb fragment spanning the 5Ј end of exon 15 to the stop codon in exon 17 was amplified by PCR using genomic DNA from Pt 1. The forward primer harbored an XhoI restriction site followed by the Kozak consensus sequence, 5Ј-CCACCATG-3Ј, at the 5Ј end. The Kozak sequence was placed to retain the normal open reading frame of COLQ. The reverse primer carried a NotI restriction site at the 5Ј end. The PCR amplicon was cloned into a cytomegalovirus-based expression vector pCI (Promega).
We transfected C2C12 myoblasts (ATCC) using FuGENE 6 (Roche Applied Science) with a minigene carrying either R410Q or E415G in exon 16, extracted total RNA using the RNeasy Mini kit (Promega), and analyzed pre-mRNA splicing by RT-PCR spanning exons 15-17, as described elsewhere (29) .
Transfection and AChE Extraction-Plasmids encoding the wildtype or mutant form of human ColQ were cotransfected into COS cells with a plasmid encoding the wild-type human AChE T catalytic subunit using the DEAE-dextran method described previously (30) . Five g of each plasmid DNA was added to COS cells in 100-mm culture dishes in 3 ml of Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum and chloroquine and incubated for 3 h at 37°C. Cells were then washed three times with phosphate-buffered saline; 6 ml of fresh Dulbecco's modified Eagle's medium ϩ 10% fetal calf serum was added, and the dishes were incubated at 37°C for 72 h. To extract the expressed enzyme, cells were scraped from dishes in 1 ml of 50 mM Tris-HCl buffer, pH 7.4 (from now on "Tris-HCl buffer" refers to 50 mM Tris, pH 7.4), containing 0.5% Triton X-100, 1.0 mM EDTA, 1 M NaCl, leupeptin (1 g/ml), and pepstatin (2 g/ml). The crude extract was vortexed in 1.5-ml microcentrifuge tubes and centrifuged at 10,000 ϫ g for 30 min, and the supernatant was stored in 50% glycerol at Ϫ20°C until used. Aliquots (200 l) of the AChE-containing supernatant were centrifuged on 5-20% sucrose gradients in Tris-HCl buffer containing 1 M NaCl, 0.5% Triton X-100, and 1 mM EDTA, and the fractions collected were assayed for AChE activity using the Ellman method. Bacterial ␤-galactosidase (ϳ16.1 S) was included in the gradients as a marker for the A 12 -AChE. Isolation of A 12 -AChE on Heparin-Agarose Columns-Extracts from COS cells expressing wild-type or mutated collagen-tailed AChE were vortexed and centrifuged at 10,000 ϫ g for 30 min, and the supernatant was diluted to 0.2 M NaCl with Tris-HCl buffer containing 0.5% Triton X-100, 1.0 mM EDTA, leupeptin (1 g/ml), and pepstatin (2 g/ml) and loaded onto columns containing 250 l of heparin-agarose (Sigma) that had been pre-equilibrated with 1 volume of Tris-HCl buffer containing 0.2 M NaCl. The columns were washed with 5 volumes of Tris-HCl buffer containing 0.2 M NaCl and the asymmetric forms eluted with 1 ml of Tris-HCl buffer containing 1 M NaCl. The eluate containing the asymmetric AChE forms was concentrated with YM-30 Centricon concentrators (Amersham Biosciences) and diluted in Tris-HCl buffer containing 0.2 M NaCl. To verify that indeed only the collagen-tailed AChE forms were being retained on the column and eluted, the eluates were analyzed by velocity sedimentation. ␤-Galactosidase (ϳ16. A, positions of CTD mutations in collagen-tailed AChE. Shaded circles represent 12 catalytic subunits, and black lines represent triple helical ColQ subunits, one attached to each tetramer. B, alignment of CTD of Torpedo, mouse, rat, and human ColQ and mutations in human ColQ. Residues conserved in three or more species are boxed. Right column indicates codon numbers of the rightmost residue. C, schematic presentation of human wild-type CTD at codons 292-455, and nine mutant constructs analyzed for insertion competence to the frog NMJ. Closed circles represent missense mutations. S312G/R410Q is a double mutation on a single allele in Pt 1. None of these mutations abolishes assembly of the collagen-tailed AChE form (A 12 ), as determined by velocity sedimentation analysis, and all can bind to heparin-agarose columns.
showed that only the collagen-tailed AChE forms are retained on the heparin column and specifically eluted with 1 M NaCl.
Transplantation of AChE to Frog Neuromuscular Junctions-The method of Rotundo et al. (27) was used with minor modifications. Frog (Rana pipiens) gastrocnemius muscles were excised, snap-frozen by immersion of the muscle in 2-methylbutane cooled with liquid nitrogen, and stored frozen at Ϫ80°C. Ten-m cross-sections from the belly of the muscle were cut in a Leica CM1900 cryostat at Ϫ20°C, adhered to Gold Seal microscope slides, and stored at Ϫ80°C until used. For analysis, the slides were brought to room temperature; excess moisture was removed, and plastic wells for transplantation and immunological staining were affixed to the slides using rubber cement. Stock asymmetric AChE solutions used for transplantation were eluted from heparin columns with Tris-HCl buffer containing 1 M NaCl and concentrated. For addition to sections, the stock solutions were diluted in Tris-HCl buffer containing 1 M NaCl and 5 mg/ml each of bovine serum albumin, chicken ovalbumin, and gelatin (all from Sigma) to give 1-2 ng of AChE/well final, and the NaCl concentration was adjusted to 0.5 M. The ionic strength of the enzyme solution (100 l/well) was adjusted stepwise over a period of 3 h to 0.3 M to prevent aggregation of collagentailed AChE forms. After addition of the enzyme preparation, the wells were sealed with coverslips, placed in a humidified chamber, and incubated overnight at room temperature. The sections were then washed for 2 h with Tris-HCl buffer containing 0.2 M NaCl and the protein mixture described above prior to processing for immunofluorescence. The specific binding is not disrupted by high salt concentrations (1 M NaCl) or heparin (500 g/ml) (27) .
Immunofluorescence-Colocalization of AChE with AChR was visualized with a Leica DMRA fluorescence microscope. AChRs were labeled with rhodamine-labeled ␣-bungarotoxin (1 g/ml), and human AChE was detected with a primary mouse anti-human AChE monoclonal AE3 that does not recognize frog AChE (31) (10 g/ml) followed by a fluorescein isothiocyanate-conjugated rabbit anti-mouse second antibody (10 g/ml). Muscle sections were fixed in 4% paraformaldehyde in phosphate-buffered saline, mounted in glycerol containing pphenylenediamine (1 mg/ml), 0.02 M sodium bicarbonate, pH 9.5 and 0.06ϫ phosphate-buffered saline, and sealed with clear nail polish.
In Vitro Perlecan Binding Assay-Plasmids encoding the indicated HSBD mutants of human ColQ cDNAs were cotransfected into COS cells with the plasmid encoding the wild-type human AChE T catalytic subunit, and the A 12 -AChE was isolated and tested for its ability to bind immobilized perlecan. The microtiter plate perlecan binding assay developed by Vigny et al. (32) was used with 10 ng of perlecan, and the heparan sulfate proteoglycan was isolated from the mouse EngelbrethHolm-Swarm sarcoma cells (Sigma) per well (see Fig. 10A for an example). A 12 -AChE harboring mutations HSBD-del and HSBD-NQGG described earlier as well as wild-type A 12 and G 1 /G 2 globular forms of AChE were added to the polystyrene microtiter plates in a total volume of 200 l. Plates were incubated overnight at 4°C, washed with TrisHCl buffer containing 0.2 or 1 M NaCl, and the bound AChE activity was determined by the Ellman method. In contrast to wild-type collagentailed AChE, the globular G 1 /G 2 and G 4 AChE forms exhibited little or no binding to immobilized perlecan in vitro.
RESULTS
Mutation Analysis-As endplate studies (Pts 1 and 2) and clinical features (Pts 1-3) indicated endplate AChE deficiency, we directly sequenced COLQ and found that each patient carried two mutant COLQ alleles (Fig. 1, A and C) . Pt 1 carried three missense mutations in CTD (S312G, R410Q, and E415G). We previously reported R410Q in another unrelated patient (23) . Family analysis in Pt 1 showed that S312G and R410Q were on the paternal allele, whereas E415G was on the maternal allele (Fig. 2) .
Pt 2 was heterozygous for R410P in CTD and for a previously reported 107del215 affecting the proline-rich attachment domain (25) . The 107del215 mutation is a consequence of skipping of exons 2 and 3 in mRNA. The cause of exon skipping could not be determined at the genomic DNA level. Cloning cDNA fragments spanning R410P and 107del215 revealed that the two mutations were heteroallelic. Pt 3 was homozygous for a previously reported Q371X in CTD (23) .
Arg-410 and Glu-415 are conserved across species, but Ser-312 is not (Fig. 1B) . Moreover, rodents use glycine at a residue corresponding to human Ser-312. None of the four missense mutations was present in 200 normal alleles.
Sedimentation Profiles of CTD Mutants-We next examined the effects of the three novel CTD mutations (S312G in Pt 1, R410P in Pt 2, and E415G in Pt 1) on formation of asymmetric AChE species in COS cells. All CTD mutations yielded asymmetric AChE species like wild-type ColQ and like five previously reported CTD mutants (Fig. 3) . R410P and E415G additionally produced an ϳ10.5 S mutant peak (M species) (Fig. 3) , also like five previously reported CTD mutants (23, 22) .
We previously reported (22) and here reproduced (data not shown) that human R315X mutant forms asymmetric AChE species in COS cells. This is in contrast to a recent report by Bon et al. (33) that Torpedo R315X produces no asymmetric AChE forms in COS cells. The apparent contradiction may represent species specificity of the trimerization domain of ColQ. An alternative possibility is that R315X affects the thermal stability of the Torpedo ColQ, which is normally expressed at temperatures of less than 10°C, but was artificially expressed at 37°C in COS cells. To examine the requirement for the CTD in AChE attachment at the endplates, we examined anchoring of the three novel (S312G, R410P, and E415G) and five previously reported (R315X, Q371X, D342E, R410Q, and C444Y) CTD mutants to the synaptic basal lamina.
Isolation of Wild-type and C-terminal Domain Mutant Collagen-tailed AChE Forms Using Heparin-Agarose Columns-
The collagen-tailed forms of AChE bind to immobilized heparin and can be eluted at high salt concentrations, showing that these interactions are electrostatic (9, 10) . COS cells transfected with the wild-type AChE T and wild-type ColQ express globular forms of AChE including monomers (G 1 ), dimers (G 2 ), tetramers (G 4 ), and collagen-tailed forms of AChE consisting of one (A 4 ), two (A 8 ), and three (A 12 ) tetramers attached to the triple helical ColQ (Fig. 4A) . To enrich for the collagen-tailed AChE, we chromatographed the COS cell extracts on heparinagarose columns and eluted with 1 M NaCl as described by Brandan and Inestrosa (9) . To confirm that only collagen-tailed AChE forms were retained on the columns and specifically eluted at 1 M NaCl, we compared sedimentation profiles of pre-and post-heparin column preparations. When cell extract containing wild-type and R410Q-ColQ was purified via heparin-agarose, only the asymmetric forms were retained on the column and subsequently eluted with 1 M NaCl (Fig. 4) . Similar results were obtained with all nine CTD and two HSBD mutants used in the present study.
Human Wild-type Asymmetric AChE Colocalizes with Frog AChR-To determine the validity of the transplantation assay using human AChE, the insertion competence of AChE attached to wild-type ColQ was compared with that of the globular G 1 /G 2 forms (AChE T subunits) alone or negative controls containing no AChE. Frozen sections of frog muscle were incubated overnight with partially purified wild-type collagentailed AChE, globular AChE, or buffer alone as described under
FIG. 4. Only the collagen-tailed acetylcholinesterase forms are specifically retained on and eluted from heparin-agarose columns.
Crude extracts from COS cells expressing wild-type or mutant collagen-tailed AChE were loaded on heparin-agarose columns and washed, and the collagen-tailed forms were eluted with Tris-HCl buffer containing 1 M NaCl. To verify that indeed only the collagen-tailed AChE forms were being retained on the column and eluted, the eluates were analyzed by velocity sedimentation. ␤-Galactosidase (ϳ16.1 S) was included in the gradients as a position marker for the collagen-tailed AChE form. By using this procedure, only the collagen-tailed AChE forms were retained on the heparin columns and specifically eluted with 1 M NaCl. "Experimental Procedures." On every slide, rhodamine ␣-bungarotoxin was used to label the AChR at the frog NMJs. The bound human AChE was visualized with the monoclonal AE3 anti-AChE antibody (31) and a second fluorescein isothiocyanate-conjugated rabbit anti-mouse antibody. Indirect immunofluorescence localization showed that human wild-type asymmetric AChE attaches to the frog synaptic basal lamina where it colocalizes with the sites of AChR accumulation (Fig. 5) . Incubation of the muscle specimens with only the primary and secondary antibodies used for labeling revealed no signal for human AChE at the frog NMJ, indicating that the antibody against human AChE did not cross-react with frog AChE (Fig.  5) . Similar studies using only the globular forms of AChE also showed lack of AChE binding (Ref. 27 and data not shown), indicating that only the collagen-tailed AChE form binds to the NMJ. (Fig.  1) to the frog NMJs (Figs. 6 and 7) . COS cells were cotransfected with wild-type AChE T and mutant ColQ. The heparin column-isolated asymmetric AChE was added to sections of frog muscle, and the colocalization of bound AChE with AChRs was visualized using mouse anti-human AChE monoclonal AE3 antibody and rhodamine-labeled ␣-bungarotoxin, respectively. These studies revealed that ColQ harboring R315X, D342E, Q371X, R410P, R410Q, and the double mutant S312G/ R410Q were insertion-incompetent (Fig. 6) . In contrast to those mutants, ColQ harboring S312G, E415G, and C444Y did insert into the frog synaptic basal lamina and colocalized with AChR (Fig. 7) . These results establish that CTD mutations impair insertion competence of ColQ and that CTD is essential for anchoring of ColQ to the synaptic basal lamina.
Transplantation of ColQ C-terminal Domain Mutants to the Frog Synapse-We next transplanted nine CTD mutants

Collagen-tailed Forms of AChE Harboring Mutations in the Heparan Sulfate Binding Domain Are Retained on HeparinAgarose Columns but Are Insertion-incompetent-We next tested if
HSBDs of ColQ are also required for anchoring ColQ to the synaptic basal lamina using the heterologous transplantation system. To this end, we constructed two types of ColQ mutants. In the HSBD-del construct, two HSBDs were abrogated by deleting RKG codons at the first HSBD and KRG codons at the second HSBD. In the HSBD-NQGG construct, RKGR codons at the first HSBD and KRGK codons at the second HSBD were both substituted to NQGG codons.
Although testing various approaches for enriching the HSBD mutant collagen-tailed AChEs, we observed that they were retained on the heparin-agarose columns at 0.2 M NaCl and specifically eluted at 1 M NaCl, as described by Deprez and Inestrosa (34) . Velocity sedimentation analysis of the total cell extracts and post-column high salt eluates indicated marked enrichment of the mutant collagen-tailed AChE (Fig. 8) . The fact that the asymmetric forms of both the HSBD-del and HSBD-NQGG mutants were retained on and specifically eluted from heparin columns in our study is also consistent with the observations of Deprez et al. (35) with rat AChE, where deletions of basic residues central to and neighboring both the Nand C-terminal HSBDs did not completely abolish heparin binding.
In contrast to wild-type AChE, no colocalization of AChR FIG. 5 . AChE containing wild-type human ColQ colocalizes with AChRs at the frog NMJ. Plasmids encoding the wild-type human AChE T catalytic subunit and the wild-type human ColQ were cotransfected into COS cells. Two days later the AChE was extracted, and the collagen-tailed forms were isolated by affinity chromatography on heparin-agarose columns and used in the binding assay. Top panels show the colocalization of wild-type human asymmetric AChE with frog AChR. Negative controls showed no colocalization when the primary and secondary antibodies were used for labeling, but no AChE was added to the muscle sections. These studies show that normal human collagen-tailed AChE can bind specifically to the frog NMJ where it colocalizes with AChR. with AChE was observed when either HSBD-del or HSBD-NQGG was transplanted to sections of frog muscle (Fig. 9) . This establishes that the HSBDs are essential for anchoring ColQ at the NMJ.
HSBD-del and HSBD-NQGG ColQ Mutants Do Not Bind to Immobilized Perlecan in Vitro-
To determine whether the insertion incompetence of the HSBD mutants could be due to loss of interaction with perlecan, we tested binding to perlecan of wild-type asymmetric AChE, asymmetric AChE harboring HSBD mutations, and wild-type globular AChE using an in vitro solid-phase binding assay (32) (Fig. 10A) . Each AChE species was incubated with immobilized purified perlecan overnight and washed with either 0.2 or 1 M salt, and the bound AChE was assayed by the Ellman method. None of the AChE species bound perlecan after washing with 1 M NaCl, and only the wild-type asymmetric AChE species remained bound to perlecan after washing with 0.2 M NaCl (Fig. 10B) . This suggests that insertion incompetence of the HSBD mutants is because of loss of interaction with perlecan, consistent with the current model that necessitates an initial interaction via these domains prior to insertion. Interestingly, the HSBD mutants remained bound to the heparin-agarose column at 0.2 M NaCl but did not bind to perlecan-coated microtiter wells at 0.2 M NaCl. That the HSBD mutants bind to heparin-agarose but not to perlecan at 0.2 M NaCl suggests that the HSBDs have a reduced affinity for the heparan sulfate side chains of perlecan while still being able to bind to heparin due to the high density of charged moieties on the affinity column.
Does E415G Disrupt an Exonic Splicing Enhancer?-A recent report (36) suggests that 15-20% of missense mutations disrupt an exonic splicing enhancer (ESE). We therefore tested the notion that the insertion-competent E415G in the penultimate exon disrupts an ESE and hence causes aberrant splicing of pre-mRNA.
RT-PCR analysis of endplate-containing muscle cDNA of Pt 1, who carried S312G/R410Q on one allele and E415G on the other allele, revealed a normally spliced transcript as well as an exon 16-skipped transcript (Fig. 11A) . Both E415G and R410Q are on exon 16. Allele-specific RT-PCR showed that the normally spliced transcript exclusively arose from an allele carrying R410Q (Fig. 11B) , indicating that exon 16 carrying E415G is invariably skipped in the patient muscle.
We next constructed R410Q and E415G minigenes that span exons 15-17, the last three exons of COLQ. We transfected C2C12 myoblasts with a minigene and analyzed pre-mRNA splicing using RT-PCR. The R410Q minigene yielded a normally spliced transcript, whereas the E415G minigene gave rise to an exon 16-skipped transcript (Fig. 11A) , thus confirming that E415G causes skipping of exon 16.
DISCUSSION
Our studies establish that the R315X, Q371X, D342E, R410P, and R410Q mutations observed in patients with endplate AChE deficiency indeed compromise anchoring of asymmetric AChE to the synaptic basal lamina. Insertion incompetence of two truncation mutations, R315X and Q371X, suggests that essential residues for anchoring of ColQ are located downstream of codon 371, but this does not exclude the importance of residues upstream of codon 371. Indeed, insertion incompetence of D342E demonstrates that residues upstream of codon 371 are also involved in anchoring ColQ. As aspartate and glutamate are similar residues that ColQ harboring Asp-342, but not Glu-342, inserts into the synaptic basal lamina is interesting and also indicates that Asp-342 is likely an evolu- tionally conserved key residue that is essential for anchoring ColQ. Insertion incompetence of R410P and R410Q also indicates that Arg-410 plays an essential role in anchoring ColQ.
Three missense mutations, S312G, E415G, and C444Y, are able to insert into the frog NMJ. As S312G is located on the same allele as R410Q, and as R410Q is insertion-incompetent, S312G is likely a rare polymorphism or a benign mutation. The insertion incompetence of the S312G/R410Q double mutant explains why the double mutant allele is pathogenic in Pt 1. The insertion competence of E415G prompted us to screen for the splicing effect of E415G. We indeed found that E415G disrupts an ESE and causes skipping of the mutation-bearing exon 16. The ESE finder release 2.0 (exon.cshl.org/ESE/) (41) predicts that E415G mutates putative SF2/ASF-and SRp55-binding sites, but the actual ESE-binding transactivating factor has not been determined. Skipping of exon 16 causes a frameshift after codon 399, which abolishes essential residues including Arg-410 as described above. The test of this hypothesis is shown in Fig. 11 .
The manner in which C444Y causes endplate AChE deficiency remains unresolved. The expressed mutant is insertioncompetent, and C444Y does not disrupt an ESE because it is in the last exon where no ESE exists. Insertion competence of C444Y may represent the limitation of the heterologous transplantation system. C444Y may affect some unidentified steps essential for ColQ expression and anchoring at the neuromuscular junction, but cannot be detected in the transfection or transplantation systems employed in our studies.
In addition to elucidating the pathogenicity of the CTD mutations, our studies establish for the first time that both HSBD and CTD are required for anchoring ColQ to the synaptic basal lamina. The exact mechanism by which the collagen-tailed AChE attaches to the mammalian NMJ is still not fully elucidated. Previous studies (20, 37) have shown that molecules of AChE that are clustered at the vertebrate NMJ are tightly associated with the basal lamina. Additionally, specific labeling of AChE with isotopically labeled diisopropylphosphofluoridate or fasciculin and visualization by EM autoradiography has placed most of the AChE along the synaptic basal lamina and extending down along the folds of postsynaptic membrane at mammalian NMJs (38, 39) . Over the last decade, a view of how AChE is attached to the basal lamina of the postsynaptic membrane has emerged. Initially, local secretion of AChE into the cleft of the neuromuscular synapse and the ensuing electrostatic interactions with heparan sulfate chains of the proteoglycans prevalent in the extracellular matrix initially serve to "trap" the enzyme. Once AChE is localized to the NMJ, the enzyme becomes firmly attached to sites of nerve-muscle contact via non-electrostatic, possibly covalent, interactions (20, 27, 38) . These studies show that the conventional high salt buffers do not detach AChE from the synaptic basal lamina, suggesting that the density of AChE molecules at the NMJ is limited by the number of available, and at present uncharacterized, binding sites for the "non-extractable" pool of collagentailed AChE (20) .
Our current model of extracellular matrix specialization at the NMJ suggests that the collagen-tailed AChE form is local- FIG. 9 . AChE containing HSBD-del and HSBD-NQGG ColQ does not colocalize with AChRs at the frog NMJ. Human wild-type asymmetric AChE and mutant asymmetric AChE harboring mutations in the heparan sulfate binding domains were purified as described in Fig. 8 and were transplanted to 10-m sections of frog muscle. Collagen-tailed AChE harboring mutations in the heparan sulfate binding domains (HSBD) do not colocalize with AChRs at the frog NMJ. HSBDdel has a deletion of RKG codons at the first HSBD, and a deletion of KRG codons at the second HSBD. HSBD-NGGG has NQGG substitutions for both RKGR codons at the first HSBD and KRGK codons at the second HSBD.
FIG. 10. Testing the ability of heparan sulfate binding domain mutants to bind immobilized perlecan in vitro.
A, the collagen-tailed and globular forms of human ColQ AChE were prepared and tested for their ability to bind immobilized perlecan in vitro as described under "Experimental Procedures." B, in contrast to wild-type collagen-tailed AChE, collagen-tailed AChE harboring deletions (HSBD-del) or missense mutations (HSBD-NQGG) in HSBD, and wild-type globular G 1 /G 2 AChE exhibited little or no binding to immobilized perlecan after washing with 0.2 M NaCl, indicating that the HSBDs are necessary for attachment to perlecan. ized in association with the transmembrane dystroglycan complex via binding of its globular CTD to the proteoglycan perlecan. The fact that the ColQ HSBD mutants, HSBD-del and HSBD-NQGG, do not insert into the frog NMJ indicates that the HSBDs play an insertional role and supports a model requiring an initial electrostatic interaction for AChE insertion (40) . However, that the insertion-incompetent mutants are retained on the heparin-agarose column under physiological salt conditions supports the idea that the HS-HSBD interaction alone is not sufficient to bind AChE in the extracellular matrix of mammalian NMJs. We show that ColQ harboring R315X, D342E, E415G, Q371X, R410P, S312G, R410Q, S312G/R410Q, and C444Y assembles into collagen-tailed forms in culture, and each can be retained on heparin columns and eluted at high salt concentrations. This suggests that these mutants retain their ability to electrostatically interact with heparan sulfate. When the total activity of R410Q, for example, estimated from velocity sedimentation profiles of pre-and post-heparin column asymmetric AChE forms, was compared with that of wild-type AChE forms, no significant reduction of binding was observed (data not shown).
Most interesting, our observation that collagen-tailed AChE with deleted or mutated HSBDs can bind to heparin (Fig. 8 ) would be consistent with either an additional heparin-binding site(s) in the collagen tail or, more likely, electrostatic interactions between other positively charged residues of the collagen tail and heparin. However, recent studies in rat (35) have attributed all heparin binding activity of asymmetric AChE specifically to the HSBDs of ColQ; therefore, the presence of an additional site is unlikely. The isoelectric point of the wild-type collagen tail is 8.08, whereas those of the HSBD-del and HSBD-NQGG mutants are 7.65 and 6.85, respectively, calculated using the algorithm in Gene Runner version 3.05 (Hastings Software, Inc.). The loss of positively charged residues and the concomitant decrease in isoelectric point of the HSBD mutants support our observation that, although these mutants are retained and specifically eluted from heparin columns, heparin binding is severely reduced.
These studies also emphasize the fact that the heparin binding domains of ColQ alone are not sufficient to localize AChE to the NMJ. Although not sufficient, they are necessary for attachment to occur. Thus, while some CTD mutations result in normal assembly and export of the A 12 AChE molecules, truncation of ColQ distal to residue 315 and specific mutations to the CTD and HSBD regions prevent insertion of A 12 -AChE into the NMJ. Results from these studies indicate that the C-terminal domain of ColQ plays an essential role in anchoring the collagen-tailed AChE into the synaptic basal lamina.
